Day: ខែ​កក្កដា 29, 2025

Naoris is Spearheading the First Decentralized Post-Quantum Infrastructure for Web2, Web3 & Web 4WELLINGTON, FL, July 29, 2025 – (ACN Newswire via SeaPRwire.com) – Naoris Protocol, the first in production quantum-resistant blockchain and cybersecurity mesh architecture, has announced its upcoming TGE for July 31, 2025, marking a key milestone in the rollout of a new foundational security layer for the internet, designed to protect both Web3 and Web2 ecosystems from quantum and traditional threats. The $NAORIS token will launch for trading on July 31 at 12:00PM UTC / 08:00AM ET. At TGE, the initial circulating supply will be 599.260,000 NAORIS tokens, with a fully diluted valuation (FDV) of $500M FDV. The token will be available for trading on Binance Alpha, Binance Perps, and Gate.io with additional exchange listings to be confirmed. For the latest details, visit the Naoris Protocol website on July 31.In terms of utility, the $NAORIS token powers a machine-driven trust economy, enabling real-time, quantum…

HAYWARD, CALIFORNIA, July 29, 2025 – (ACN Newswire via SeaPRwire.com) – Biolog, a leading provider of microbial identification and phenotypic characterization tools and services, announced today that both its anaerobic media and anaerobic chambers have received CE marking, clearing the way for broader international use. The media and chambers were part of Biolog’s acquisition of Anaerobe Systems earlier this year with the objective of bringing class-leading tools for microbiology to the rapidly growing clinical, microbiome, and agricultural markets.Today, Biolog’s TruPRAS™ media is the only commercial media manufactured under true pre-reduced, anaerobically sterilized conditions, preventing the formation of harmful byproducts that can be toxic to anaerobic organisms. This line of media products, which has been approved for In Vitro Diagnostic (IVD) use by the USA FDA for years, has now also achieved CE marking under the requirements of the EU IVDR regulation 2017/746. With zero recalls or field actions throug…

HONG KONG, July 29, 2025 – (ACN Newswire via SeaPRwire.com) – July 25, Guotai Junan International Holdings Limited (“GTJAI” or the “Company”, stock code: 1788.HK), a company of Guotai Haitong Group, is pleased to announce that while actively saving energy and reducing emissions，it has successfully offset its Scope 1 and Scope 2 carbon emissions totaling 609.29 tons of carbon dioxide equivalent for the year 2024 by subscribing to the carbon credits issued under the international Verified Carbon Standard (VCS). This marks the third consecutive year that GTJAI has achieved “carbon neutrality” at the operational level, demonstrating the Company’s leading practice and commitment to green operation.The carbon credits come from “Guoluo Grassland Sustainable Management Project” located in Guoluo Tibetan Autonomous Prefecture, Qinghai Province, China. It is dedicated to the restoration of degraded grassland ecosystems, based on the holistic nature of the ecosystems, in line with the concept of ecological civilizatio…

ANKARA, Turkey, July 28, 2025 – (ACN Newswire via SeaPRwire.com) – GEN Pharmaceuticals (GENIL.IS), Türkiye’s leading specialty pharmaceutical company, announced positive results from its Phase 1 clinical trial evaluating the safety, tolerability, and pharmacokinetics (PK) of first-in-class and novel orally administered mitochondria-directed drug candidate SUL-238 in healthy elderly volunteers. The findings were presented at the Alzheimer’s Association International Conference 2025 (AAIC®) in Toronto.This single oral ascending dose (SAD) Phase 1, first-in-human, randomized, double-blind, placebo-controlled study was conducted in three parts, involving a total of 53 healthy elderly adults. Part 1 included 6 cohorts (50, 100, 250, 500, 1000, and 2000 mg orally, n=23). In Part 2, the PK of a single 1000 mg oral dose was investigated in 10 healthy elderly adults. In Part 2B, the food effect was assessed using a randomized, single oral 2000 mg dose, two-treatment, two-period, crossover design (n=20).The trial resul…

Vancouver, British Columbia–(ACN Newswire via SeaPRwire.com – July 28, 2025) – Doubleview Gold Corp (TSXV: DBG) (OTCQB: DBLVF) (WKN: LA1W038) (FSE: 1D4) (“Doubleview” or the “Company”) is pleased to announce the commencement of an advanced exploration program at its 90%-owned copper-silver-zinc-gold Red Spring Project, located in central British Columbia, Canada. This initiative marks a significant step in unlocking the project’s full potential and reinforces Doubleview’s commitment to critical mineral development.Red Spring Project: Inaugural 3D IP Survey UnderwayThe Red Spring Project, a pillar in Doubleview’s expanding portfolio, is situated in a highly prospective region of central British Columbia, Canada. The Company holds a 90% interest in this compelling copper-silver-zinc-gold project, which has demonstrated strong mineralization in historical drilling, particularly in its central zone. Decades of previous operator activities, including sampling, geophysical surveys, and approximately 4,000 feet of …

Tokyo, Japan, July 28, 2025 – (ACN Newswire via SeaPRwire.com) –  Quantum Solutions Co., Ltd. (2338.T) and its affiliates (the “Quantum Solutions’ Group” or “Quantum Solutions”), a Tokyo Stock Exchange-listed company, today announced a new strategic milestone in its digital asset initiative. The Quantum Solutions’ Group, has entered into a business collaboration arrangement with TDX Strategies Ltd, a renowned digital asset technology company in Asia. The two parties will cooperate extensively in areas including Bitcoin trade execution, asset custody, structured product design, and market risk management—offering end-to-end technical and service support for Quantum Solutions’ Bitcoin Treasury strategy.Quantum Solutions previously disclosed its plan to accumulate up to 3,000 Bitcoins over the next 12 months, aiming to hedge inflation risks, optimize asset structure, and enhance the agility of its financial system. The collaboration with TDX Strategies marks a key transition from capital planning to systemized e…

SHENZHEN, CHINA, July 29, 2025 – (ACN Newswire via SeaPRwire.com) – China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that on 28 July 2025, the New Drug Application (NDA) for improved new drug ZUNVEYL (Benzgalantamine Gluconate Enteric-coated Tablets) (“ZUNVEYL” or the “Product”) has been accepted by the National Medical Products Administration of China (NMPA). The Product is indicated for the treatment of mild-to-moderate dementia of the Alzheimer’s type in adults.About Product ZUNVEYLZUNVEYL was approved in July 2024 by the U.S. Food and Drug Administration (FDA) for the treatment of mild-to-moderate dementia of the Alzheimer’s type in adults. As a new generation of acetylcholinesterase inhibitor (AChEI), ZUNVEYL can inhibit the acetylcholinesterase from breaking down the neurotransmitter acetylcholine, increase the level of acetylcholine in the central nervous system, and therefore alleviate cognition and memory impairment in Alzheimer’s disease patients. As a prodrug of g…